Cancer- and cardiac-induced cachexia: Same fate through different inflammatory mediators?

• Type: Another Publication in an International Scientific Journal
• Date: 2022

Authors

Rita Nogueira-Ferreira (Author) Other; Fábio Sousa-Nunes (Author) Other; Adelino Leite-Moreira (Author) FMUP; Liliana Moreira-Costa (Author) Other; Rui Vitorino (Author) Other; Lúcio Lara Santos (Author) Other; Daniel Moreira-Gonçalves (Author) FADEUP; Rita Ferreira (Author) Other

Journal

Title: Inflammation Research

Vol. 71 No. 7-8

Pages: 771-783

ISSN: 1023-3830

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 4 Citations

Scopus - 4 Citations

Scientific classification

FOS: Social sciences

Other information

Authenticus ID: P-00W-Q42

DOI: 10.1007/s00011-022-01586-y

Abstract (EN): Background Inflammation is widely recognized as the driving force of cachexia induced by chronic diseases; however, therapies targeting inflammation do not always reverse cachexia. Thus, whether inflammation per se plays an important role in the clinical course of cachectic patients is still a matter of debate. Aims To give new insights into cachexia's pathogenesis and diagnosis, we performed a comprehensive literature search on the contribution of inflammatory markers to this syndrome, focusing on the noncommunicable diseases cancer and cardiovascular diseases. Methods A systematic review was performed in PubMed using the keywords (cancer OR cardiac cachexia AND human OR patient AND plasma or serum). A total of 744 studies were retrieved and, from these, 206 were selected for full-text screening. In the end, 98 papers focusing on circulating biomarkers of cachexia were identified, which resulted in a list of 113 different mediators. Results Data collected from the literature highlight the contribution of interleukin-6 (IL-6) and C-reactive protein (CRP) to cachexia, independently of the underlying condition. Despite not being specific, once the diagnosis of cachexia is established, CRP might help to monitor the effectiveness of anti-cachexia therapies. In cardiac diseases, B-type natriuretic peptide (BNP), renin, and obestatin might be putative markers of body wasting, whereas in cancer, growth differentiation factor (GDF) 15, transforming growth factor (TGF)-beta 1 and vascular endothelial growth factor (VEGF) C seem to be better markers of this syndrome. Independently of the circulating mediators, NF-kappa B and JAK/STAT signaling pathways play a key role in bridging inflammation with muscle wasting; however, therapies targeting these pathways were not proven effective for all cachectic patients. Conclusion The critical and integrative analysis performed herein will certainly feed future research focused on the better comprehension of cachexia pathogenesis toward the improvement of its diagnosis and the development of personalized therapies targeting specific cachexia phenotypes.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 13